Vertex tiptoes further into Duchenne research with Tevard deal

An alliance with the startup brings Vertex an RNA-based medicine for the disease, adding to a portfolio that already includes a gene editing treatment.

By Ben Fidler • Feb. 28, 2023

Theravance, under pressure from activist investor, cuts back research, trims staff

The company is laying off 17% of its workforce and stopping work on inhaled JAK inhibitors in its latest restructuring move.

By Ned Pagliarulo • Feb. 28, 2023

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

How life sciences benefits from broader healthcare transformation

Digital transformation has much to offer life sciences as well as healthcare — and the synergies between the two can further optimize the power of digital health, clinical trials and patient outcomes.

Feb. 27, 2023

EQRx, having redrawn strategy, to trim workforce by 18%

Part of a plan to lower spending, the workforce reduction will involve layoffs as well as leaving positions unfilled after employees depart.

By Ned Pagliarulo • Feb. 24, 2023

Roche hands rights to lung cancer drug back to Blueprint

Weeks after the Swiss drugmaker wrote off Gavreto’s accounting value, the biotech will regain responsibility for its commercialization.

By Jonathan Gardner • Feb. 24, 2023

FDA approves Sanofi’s long-lasting hemophilia drug

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

By Jacob Bell • Feb. 23, 2023

Moderna shares sink amid COVID forecasts, trial news

The biotech expects to earn at least $5 billion from sales of its COVID vaccine this year, which would be about one-third of what it made in 2022.

By Delilah Alvarado • Feb. 23, 2023

Jounce to lay off half its workers, merge with UK biotech Redx

The cancer biotech will combine with Redx Pharma, with the resulting company focusing on Redx’s programs for cancer and fibrotic disease.

By Christopher Newman • Feb. 23, 2023

Rubius, after layoffs and executive turnover, sets plan to dissolve

Four years after going public with a multibillion dollar valuation, the once high-flying biotech has decided to shut down and liquidate its assets. 

By Christopher Newman • Feb. 22, 2023

Moderna inks another gene editing deal

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

By Jacob Bell • Feb. 22, 2023

Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs

There comes a time when companies with platforms need to focus on their most advanced prospects, Morrison said, rather than sink all of their funds into building the technology.

By Gwendolyn Wu • Feb. 21, 2023

Apellis wins FDA approval of first drug for type of vision loss

Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.

By Ben Fidler • Updated Feb. 17, 2023

Talaris restructures, ending effort to develop a cell therapy for kidney transplants

Following a patient death and difficulty enrolling study participants, the company is laying off a third of its staff and ending a pair of studies for a two-decade-old program once owned by Novartis.

By Ben Fidler • Feb. 16, 2023

With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem

The company’s platform technology is built on research from Zhang’s lab at the Broad Institute, which focuses on proteins that could be used to package and deliver nucleic acids.

By Gwendolyn Wu • Feb. 16, 2023

With sales falling, Biogen’s new CEO says transformation is needed

New CEO Christopher Viehbacher set the tone early into his tenure at the embattled biotech, quickly moving to cut jobs and trim research in the months that followed.

By Jacob Bell • Feb. 15, 2023

PureTech, tweaking research, trims a ‘small number’ of positions

The biotech company creator is deprioritizing work on its “Orasome” drug delivery technology after what it described as a “key go/no go” experiment.

By Ned Pagliarulo • Feb. 14, 2023

New cancer cell therapy biotech emerges, backed by MD Anderson and Replay

Syena will develop TCR-based natural killer cell therapies, building on research done by MD Anderson’s Katy Revzani and using technology from Replay.

By Delilah Alvarado • Feb. 14, 2023

GSK backs away from COVID collaboration with Vir

The British drugmaker will retain an interest in COVID antibody drug sotrovimab, which was withdrawn from the U.S. market, and a second treatment still in early-stage trials.

By Jonathan Gardner • Feb. 14, 2023

With latest startup, repeat biotech founder Craig Crews tries to ‘hold and kill’ tumors

Formed by the Yale scientist and Arvinas founder, Halda Therapeutics is developing a twist on targeted protein degradation, an area of research that’s recently caught drugmakers’ attention.

By Ben Fidler • Updated Feb. 14, 2023

A new generation of biotech leaders is emerging. Can they change how drug startups are built?

Through social media, virtual meetings and mentorship programs, a community of entrepreneurs is looking for new ways to build drug companies.

By Gwendolyn Wu • Feb. 14, 2023

Frequency to cut jobs after clinical trial setback

The biotech, which has been working on drugs for hearing loss, will lay off 55% of its workforce and discontinue work on two experimental treatments.

By Delilah Alvarado • Feb. 13, 2023

Analyze whole genome sequencing samples at the speed of light

Deliver fast and reliable results at low cost with a tool for whole genome analysis in just minutes

Feb. 13, 2023

Another biotech IPO hits the market, as Mineralys raises $192M

In pricing an IPO, Mineralys followed closely behind Structure Therapeutics’ offering, suggesting an opening investment window.

By Gwendolyn Wu • Feb. 9, 2023

FDA offers former biotech unicorn Intarcia a chance for a panel review

Intarcia, which once held a multibillion-dollar valuation, deflated following the FDA’s 2017 and 2020 rejections of its drug-device combination for diabetes.

By Jonathan Gardner • Feb. 9, 2023

Idorsia shares sink on ‘unexpected’ failure of drug study

The Actelion spinout’s drug clazosentan, which is approved for use in Japan, didn’t significantly outperform a placebo in a Phase 3 study of patients with a particular type of stroke.

By Ned Pagliarulo • Feb. 6, 2023